,address1,address2,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Mr. Gregory P. Madison', 'age': 54, 'title': 'CEO & Exec. Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 678000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
1,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Dr. Christian  Schweiger M.D., Ph.D.', 'age': 55, 'title': 'Co-Founder & Non Exec. Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 45000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
2,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Mr. Hans-Peter  Rudolf', 'title': 'Chief Financial Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
3,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Ms. Lucy Kate Huntington-Bailey', 'title': 'Gen. Counsel & Company Sec.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
4,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Ms. Suzanne  Wood', 'title': 'Group HR Director', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
5,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Ms. Carol  Akinola', 'title': 'Head of Pharmacovigilance & Medical Information', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
6,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Mr. Andrew  Hurley', 'age': 53, 'title': 'Chief Commercial Officer', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
7,Northern Design Centre,Baltic Business Quarter,Gateshead,NE8 3DF,United Kingdom,44 1915 118 500,https://www.shieldtherapeutics.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",27,"{'maxAge': 1, 'name': 'Kate  Armanetti', 'title': 'Sr. Director of People & Culture', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,10.625,10.56,10.0,10.56,10.625,10.56,10.0,10.56,0.0,1.166666,-36.160713,743249,743249,1994110,1264186,1264186,10.0,10.25,0,0,73977504,5.8,12.5,16.560892,9.9425,7.66275,0.0,0.0,GBp,29073036,0.0,124371358,713036032,0.65958,0.16863,0.021,482.14285,1672444800,1703980800,1672444800,-40444000,-0.16,-0.28,6.508,-1.208,LSE,EQUITY,STX.L,STX.L,SHIELD THERAPEUTICS PLC ORD 1.5,Shield Therapeutics plc,1456473600,Europe/London,BST,3600000,10.125,59.0,45.0,52.0,52.0,none,2,2821000,0.011,-24076000,5631000,0.617,0.949,4467000,103.759,0.019,-0.48330003,-1.7539301,1997000,-10208625,-17312000,1.347,0.44706002,0.0,-5.75465,GBP,
